CHARACTERISTICS OF TARGET ORGAN CONDITION IN PATIENTS WITH SATISFACTORY OFFICE CONTROL OF ARTERIAL HYPERTENSION
Abstract
Introduction. Arterial hypertension (AH) is observed in approximately 1.3 billion people living in the modern world. The search for early markers of target organ damage in hypertension continues to be relevant. Purpose of the study. To evaluate the indicators of the structural and functional state of the retina, left heart and kidneys in patients with arterial hypertension (AH) who have satisfactory disease control according to office blood pressure (BP) measurements against the background of combination antihypertensive therapy (AHT). Methods and design. We examined 87 patients (65 males and 22 females, mean age 50.5 ± 4.87 years) with stage I or II hypertension with office blood pressure (BP) < 140/90 mmHg against the background of the use of double combined AHT (main group) and 71 subjects without a history of AH (46 males and 25 females, average age 49.9 ± 4.92 years) (control group). We carried out laboratory and instrumental screening of the condition of target organs (kidneys, heart, eye fundus), and provided a comparative description of the studied indicators in individuals of the study and control groups, taking into account gender. Statistical data processing was carried out using the Basic Statistics / Tables (basic statistics and tables) and ANOVA (analysis of variance) modules of the statistical data processing software package STATISTICA 10. Results. Patients with AH compared to normotensive individuals within the reference range of values had higher values of 24-h albuminuria (p = 0.01), albumin-creatinine ratio (ACR) (p = 0.09), Sokolov–Lyon index (p < 0.001), amplitude of the R wave in lead aVL (p = 0.03), Cornell voltage product (p < 0.001), left ventricular myocardial mass index (LVMI) (p < 0.001). Males and females with hypertension compared to males and females with normotension had higher values: ACR (p = 0.04 and p = 0.05, respectively), Sokolov-Lyon index (p = 0.001 and p = 0.006, respectively), LVMI (g/ m²) (p < 0.001 and p = 0.005, respectively), foveal avascular zone (FAZ) (p = 0.08 and p = 0.10, respectively). Conclusions. Values of ACR, 24-h albuminuria, LVMI, FAZ area in middle-aged patients with an office BP level of < 140/90 mm Hg during treatment correspond to the reference range of values, but significantly exceed similar indicators in peers without a
history of hypertension, regardless of gender.
References
Барсуков А.В., Ясеновец М.В., Щербакова К.А. и др. Глазное дно как орган-мишень при гипертонической болезни: обзор литературы. CardioСоматика. 2022; 13(4): 213–222. DOI: 10.17816/CS196005.
Бойцов С.А., Погосова Н.В., Аншелес А.А. и др. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российский кардиологический журнал. 2023; 28(5): 5452. DOI: 10.15829/1560-4071-2023-5452.
Горбунов В.М., Смирнова М.И., Курехян А.С., Драпкина О.М. Оценка клинического и амбулаторного артериального давления в практической работе врача первичного звена здравоохранения. Методические рекомендации. Кардиоваскулярная терапия и профилактика. 2023; 22(7): 3666. DOI: 10.15829/1728-8800-2023-3666.
Кобалава Ж.Д., Конради А.О., Недогода С.В. и др. Клинические рекомендации. Артериальная гипертензия у взрослых. Российский кардиологический журнал. 2020; 25(3): 149–218. DOI: 10.15829/1560-4071-2020-3-3786.
Парцерняк А.С., Крюков Е.В., Цыган В.Н. и др. Метаболический синдром и атеросклероз у молодых мужчин. Лечение и профилактика. 2021; 11(4): 5–11.
Чазова И.Е., Жернакова Ю.В. [от имени экспертов]. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16(1): 6–31.
Чазова И.Е., Кисляк О.А., Подзолков В.И. и др. Артериальная гипертензия и хроническая болезнь почек: консенсус по ведению пациентов. Системные гипертензии. 2023; 20(1): 5–19. DOI: 10.38109/2075-082X-2023-1-5-19.
Юнкеров В.И. Основы математико-статистического моделирования и применения вычислительной техники в научных исследованиях. СПб.: ВМедА; 2000: 140.
Юнкеров В.И., Григорьев С.Г., Резванцев М.В. Математико-статистическая обработка данных медицинских исследований. 3-е изд., доп. СПб.: ВМедА; 2011: 318.
Heitmar R., Varma C., De Graefes P. et al. The relationship of systemic markers of renal function and vascular function with retinal blood vessel responses. Arch Clin Exp Ophthalmol. 2016; 254(11): 2257–65. DOI: 10.1007/s00417-016-3432-9.
Kraus M.F., Potsaid B., Mayer M.A. et al. Motion correction in optical coherence tomography volumes on a per A-scan basis using orthogonal scan patterns. Biomed Opt Express. 2012; 3(6): 1182–99.
Levin A., Stevens P.E., Bilous R.W. et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3: 1–150. DOI: 10.1038/kisup.2012.73.
Lim H.B., Lee M.W., Park J.H. et al. Changes in ganglion cell-inner plexiform layer thickness and retinal microvasculature in hypertension: an optical coherence tomography angiography study. Am J Ophthalmol. 2019; 199: 167–76. DOI: 10.1016/j.ajo.2018.11.016.
Mancia G., Fagard R., Narkiewicz K. et al. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension. J Hypertens. 2013; 31(7): 1281–1357. DOI: 10.1097/01.hjh.0000431740.32696.cc.
Mancia G., Kreutz R., Brunström M. et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023. DOI. 10.1097/HJH.0000000000003480.
Márquez D.F., Rodríguez-Sánchez E., de la Morena J.S. et al. Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts. Nefrologia (Engl Ed). 2022; 42(5): 519–30.
Murakami T., Satoh M., Metoki H. Long-term changes in blood pressure and their health impact. Hypertens Res. 2023. DOI: 10.1038/s41440-023-01446-0.
Rizzoni D., Mengozzi A., Masi S. et al. New noninvasive methods to evaluate microvascular structure and function. Hypertension. 2022; 79: 874–86.
Schrader J., Luders S., Zuchner C. et al. Practice vs ambulatory blood pressure measurement under treatment with ramipril (PLUR Study): a randomised, prospective long-term study to evaluate the benefits of ABPM in patients on antihypertensive treatment. J Hum Hypertens. 2000; 14: 435–40.
Volpe M., Battistoni A., Tocci G. et al. Cardiovascular risk assessment beyond systemic coronary risk estimation: a role for organ damage markers. J Hypertens. 2012; 30: 1056–64. DOI: 10.1097/HJH.0b013e3283525715.
Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33): 3021–3104. DOI: 10.1093/eurheartj/ehy339.
Zheng W., Mu J., Yan Y. et al. Associations of blood pressure trajectories in early life with target organ damage in midlife: a 30-year cohort study. Hypertens Res. 2023. DOI: 10.1038/s41440-023-01387-8.
Zhou B., Carrillo-Larco R., Danaei G. et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021; 398(10304): 957–80. DOI: 10.1016/S0140-6736(21)01330-1.
